Clinical Trial Update: Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of TAS-102 with bevacizumab as maintenance therapy after induction in metastatic colorectal cancer; study TERMINATED with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Georgetown University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-08-07